DelMar Pharmaceuticals has awarded Dr. Madan Kwatra a three-year, $715,500 grant, titled “Development of VAL-083, alone or in combination with other agents, to inhibit the growth of specific subsets of glioblastoma (personalized drug development).”
Glioblastoma (GBM) is a deadly brain cancer, and attempts to control its progression have been limited. The current standard of care consists of surgery followed by radiation and chemotherapy using temozolomide. However, temozolomide only works for about 40 percent of GBM patients who have a methylated MGMT promoter. In contrast, VAL-083 is a novel chemotherapeutic agent that has activity against GBM with both methylated and unmethylated MGMT promoters. Thus, VAL-083 is a more versatile chemotherapeutic agent that may help a wider subset of GBM patients.
The completion of the proposed pre-clinical studies will identify molecular characteristics of GBM tumors that are more likely to respond to VAL-083 therapy either alone, or through combination therapies. This personalized medicine approach will be used to initiate clinical trials in newly diagnosed GBM patients.